ArticleFrontiers in cardiovascular medicine2026
Corvad as a bridge to LVAD implantation in end-stage heart disease complicated by cardiogenic shock: a three-case series.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the safety, hemodynamic efficacy, and short-term outcomes of CorVad mechanical circulatory support as a bridge to left ventricular assist device (LVAD) therapy for cardiogenic shock and the changes in related hemolysis indicators. Methods: We retrospectively analyzed three patients with Society for Cardiovascular Angiography and Interventions (SCAI) stage D Cardiogenic shock (CS) admitted between November 2024 and May 2025 to the First Affiliated Hospital of Anhui Medical University. All received CorVad support and were bridged to LVAD. Hemodynamic parameters, short-term prognosis, and dynamic changes in hemoglobin (Hb), hematocrit (Hct) and Indirect bilirubin within 24 h post-implantation were assessed. Results: CorVad support led to rapid improvements in mean arterial pressure, cardiac output, and cardiac index, accompanied by a marked reduction in lactate. All three patients successfully underwent elective LVAD implantation without procedural complications or in-hospital mortality. All patients remained alive and ambulatory at 30-day and 3-month follow-up. Within 24 h post-implantation, Hb, Hct declined modestly and indirect bilirubin levels have slightly increased, suggesting mild hemolysis or transient hemodilution, without severe hemolysis-related complications. Conclusion: CorVad provides effective and timely hemodynamic rescue in patients with CS, enabling safe transition to durable LVAD implantation, with favorable short-term prognosis. Serial monitoring of hemolysis-related indicators is required postoperatively to identify and manage potential hemolysis risks at an early stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.